What makes synthetic DNA the better choice for gene therapy development?

As gene therapy continues to advance, the need for safer, faster, and more flexible DNA solutions is pushing the industry beyond traditional plasmid DNA. In this article, Drug Discovery News explores how synthetic DNA is emerging as a suitable alternative, with advantages including: faster production timelines, higher purity, and the elimination of bacterial components.

COO Amy Walker shares insights into 4basebio’s proprietary DNA formats, the recent achievement of GMP certification, and how the company supports gene therapy developers from discovery to clinical application. Learn how synthetic DNA not only reduces production time from months to weeks, but also offers greater scalability, safety, and customization for a range of advanced therapeutic applications.